CPX-315

CPX-315 is not a recognized pharmaceutical agent or clinical-stage drug candidate; based on the provided context and clinical trial data, it appears to be a typographical error for **CPX-351** (brand name **Vyxeos**). CPX-351 is a liposomal, dual-drug nanoparticle formulation containing **cytarabine** (an antimetabolite) and **daunorubicin** (an anthracycline/topoisomerase II inhibitor) encapsulated at a fixed 5:1 molar ratio. This specific ratio is designed to exploit drug-drug synergy to enhance antileukemic efficacy while reducing systemic toxicity. The drug is primarily indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). It has been studied in phase III trials (e.g., ALFA 2101) showing superior overall survival compared to standard 7+3 chemotherapy in high-risk AML populations.